Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and α-synuclein pathology, manifesting clinically by motor symptoms such as tremor, rigidity, and bradykinesia, alongside cognitive and other non-motor impairments.1 While pathogenic mutations in LRRK2 and GBA are known to influence disease susceptibility and clinical course, there are likely additional genetic factors contributing to variability in disease manifestation. Here, LRRK2 is linked to Parkinson disease.